Antibody data
- Antibody Data
- Antigen structure
- References [17]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 20618-1-AP - Provider product page

- Provider
- Proteintech Group
- Product name
- FAM83A antibody
- Antibody type
- Polyclonal
- Description
- FAM83A antibody (Cat. #20618-1-AP) is a rabbit polyclonal antibody that shows reactivity with human and has been validated for the following applications: IHC, WB, ELISA.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references FAM83A may serve as a potential prognostic indicator for stomach adenocarcinoma.
FAM83A is a prognostic biomarker for lung squamous cell carcinoma and correlated with immunoregulation.
TFAP2A upregulates FAM83A to suppress ferroptosis and diminish cisplatin sensitivity in non-small cell lung cancer.
Diagnostic value of immune-related biomarker FAM83A in differentiating malignant from benign pleural effusion in lung adenocarcinoma.
Screening and identification of miRNAs negatively regulating FAM83A/Wnt/β-catenin signaling pathway in non-small cell lung cancer.
Family with sequence similarity 83, member A (FAM83A) inhibits ferroptosis via the Wnt/β-catenin pathway in lung squamous cell cancer.
High-risk histological subtype-related FAM83A hijacked FOXM1 transcriptional regulation to promote malignant progression in lung adenocarcinoma.
FAM83A promotes the progression and metastasis of human pancreatic neuroendocrine tumors by inducing the epithelial-mesenchymal transition via the PI3K/AKT and ERK pathways.
Genomic analysis and filtration of novel prognostic biomarkers based on metabolic and immune subtypes in pancreatic cancer.
Lovastatin inhibits erythroleukemia progression through KLF2-mediated suppression of MAPK/ERK signaling.
Aberrant epigenetic and transcriptional events associated with breast cancer risk.
FAM83A is a potential biomarker for breast cancer initiation.
FAM83A has a pro-tumor function in ovarian cancer by affecting the Akt/Wnt/β-catenin pathway.
Long non-coding RNA FEZF1-AS1 promotes rectal cancer progression by competitively binding miR-632 with FAM83A.
FAM83A promotes proliferation and metastasis via Wnt/β-catenin signaling in head neck squamous cell carcinoma.
Involvement of MicroRNA-1-FAM83A Axis Dysfunction in the Growth and Motility of Lung Cancer Cells.
Positive feedback loop of FAM83A/PI3K/AKT/c-Jun induces migration, invasion and metastasis in hepatocellular carcinoma.
Song DF, Gu ZQ, Qi L, Wu YM, Wang L, Jin MR, Li ZG, Li YJ
Translational cancer research 2025 Sep 30;14(9):5425-5440
Translational cancer research 2025 Sep 30;14(9):5425-5440
FAM83A is a prognostic biomarker for lung squamous cell carcinoma and correlated with immunoregulation.
Peng C, Kong X, Hui Y, Yang X, Hou Y, Sheng W, Yuan J, Fei X, Wang K, Nian J, Yu W
Scientific reports 2025 Oct 21;15(1):36590
Scientific reports 2025 Oct 21;15(1):36590
TFAP2A upregulates FAM83A to suppress ferroptosis and diminish cisplatin sensitivity in non-small cell lung cancer.
Sun Q, Qu W, Wang Y, Yang K, Weng Y
Cell division 2025 Jul 11;20(1):19
Cell division 2025 Jul 11;20(1):19
Diagnostic value of immune-related biomarker FAM83A in differentiating malignant from benign pleural effusion in lung adenocarcinoma.
Liu H, Yao J, Liu Y, Wu L, Tan Z, Hu J, Chen S, Zhang X, Cheng S
Discover oncology 2024 Jun 24;15(1):242
Discover oncology 2024 Jun 24;15(1):242
Screening and identification of miRNAs negatively regulating FAM83A/Wnt/β-catenin signaling pathway in non-small cell lung cancer.
Yuan W, Liu W, Huang H, Chen X, Zhang R, Lyu H, Xiao S, Guo D, Zhang Q, Ali DW, Michalak M, Chen XZ, Zhou C, Tang J
Scientific reports 2024 Jul 29;14(1):17394
Scientific reports 2024 Jul 29;14(1):17394
Family with sequence similarity 83, member A (FAM83A) inhibits ferroptosis via the Wnt/β-catenin pathway in lung squamous cell cancer.
Wang C, Zhang J, Wang H, Chen R, Lu M
Cell death discovery 2024 Jul 20;10(1):332
Cell death discovery 2024 Jul 20;10(1):332
High-risk histological subtype-related FAM83A hijacked FOXM1 transcriptional regulation to promote malignant progression in lung adenocarcinoma.
Fei W, Yan Y, Liu G, Peng B, Liu Y, Chen Q
PeerJ 2023;11:e16306
PeerJ 2023;11:e16306
FAM83A promotes the progression and metastasis of human pancreatic neuroendocrine tumors by inducing the epithelial-mesenchymal transition via the PI3K/AKT and ERK pathways.
Zhou B, Zhou X, Zhan C, Jin M, Yan S
Journal of endocrinological investigation 2023 Jun;46(6):1115-1130
Journal of endocrinological investigation 2023 Jun;46(6):1115-1130
Genomic analysis and filtration of novel prognostic biomarkers based on metabolic and immune subtypes in pancreatic cancer.
Chen G, Liu Y, Su D, Qiu J, Long J, Zhao F, Tao J, Yang G, Huang H, Xiao J, Zhang T, Zhao Y
Cellular oncology (Dordrecht, Netherlands) 2023 Dec;46(6):1691-1708
Cellular oncology (Dordrecht, Netherlands) 2023 Dec;46(6):1691-1708
Lovastatin inhibits erythroleukemia progression through KLF2-mediated suppression of MAPK/ERK signaling.
Gao J, Hu J, Yu F, Wang C, Sheng D, Liu W, Hu A, Yu K, Xiao X, Kuang Y, Zacksenhaus E, Gajendran B, Ben-David Y
BMC cancer 2023 Apr 4;23(1):306
BMC cancer 2023 Apr 4;23(1):306
Aberrant epigenetic and transcriptional events associated with breast cancer risk.
Marino N, German R, Podicheti R, Rusch DB, Rockey P, Huang J, Sandusky GE, Temm CJ, Althouse S, Nephew KP, Nakshatri H, Liu J, Vode A, Cao S, Storniolo AMV
Clinical epigenetics 2022 Feb 9;14(1):21
Clinical epigenetics 2022 Feb 9;14(1):21
FAM83A is a potential biomarker for breast cancer initiation.
Marino N, German R, Podicheti R, Rockey P, Sandusky GE, Temm CJ, Nakshatri H, Addison RJ, Selman B, Althouse SK, Storniolo AMV
Biomarker research 2022 Feb 19;10(1):8
Biomarker research 2022 Feb 19;10(1):8
FAM83A has a pro-tumor function in ovarian cancer by affecting the Akt/Wnt/β-catenin pathway.
Zhao J, Zhao F, Yang T, Tian S, Zhao M, Wang S, Yang X
Environmental toxicology 2022 Apr;37(4):695-707
Environmental toxicology 2022 Apr;37(4):695-707
Long non-coding RNA FEZF1-AS1 promotes rectal cancer progression by competitively binding miR-632 with FAM83A.
Xie R, Liu C, Liu L, Lu X, Tang G
Acta biochimica et biophysica Sinica 2022 Apr 25;54(4):452-462
Acta biochimica et biophysica Sinica 2022 Apr 25;54(4):452-462
FAM83A promotes proliferation and metastasis via Wnt/β-catenin signaling in head neck squamous cell carcinoma.
Ji H, Song H, Wang Z, Jiao P, Xu J, Li X, Du H, Wu H, Zhong Y
Journal of translational medicine 2021 Oct 12;19(1):423
Journal of translational medicine 2021 Oct 12;19(1):423
Involvement of MicroRNA-1-FAM83A Axis Dysfunction in the Growth and Motility of Lung Cancer Cells.
Liu PJ, Chen YH, Tsai KW, Yeah HY, Yeh CY, Tu YT, Yang CY
International journal of molecular sciences 2020 Nov 22;21(22)
International journal of molecular sciences 2020 Nov 22;21(22)
Positive feedback loop of FAM83A/PI3K/AKT/c-Jun induces migration, invasion and metastasis in hepatocellular carcinoma.
Liu C, Peng X, Li Y, Liu S, Hou R, Zhang Y, Zuo S, Liu Z, Luo R, Li L, Fang W
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2020 Mar;123:109780
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2020 Mar;123:109780
No comments: Submit comment
No validations: Submit validation data